These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38526855)

  • 21. [Identification of biomarkers and new therapies for taxane-induced peripheral neuropathy].
    Koyanagi M; Imai S; Nakagawa T; Matsubara K
    Nihon Yakurigaku Zasshi; 2019; 154(5):241-244. PubMed ID: 31735751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology.
    Chen EI; Crew KD; Trivedi M; Awad D; Maurer M; Kalinsky K; Koller A; Patel P; Kim Kim J; Hershman DL
    PLoS One; 2015; 10(12):e0145816. PubMed ID: 26710119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel.
    Rose PG; Smrekar M
    Gynecol Oncol; 2003 Nov; 91(2):423-5. PubMed ID: 14599877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
    Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
    Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
    JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation.
    Osmani K; Vignes S; Aissi M; Wade F; Milani P; Lévy BI; Kubis N
    J Neurol; 2012 Sep; 259(9):1936-43. PubMed ID: 22349867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer.
    Greenlee H; Crew KD; Capodice J; Awad D; Buono D; Shi Z; Jeffres A; Wyse S; Whitman W; Trivedi MS; Kalinsky K; Hershman DL
    Breast Cancer Res Treat; 2016 Apr; 156(3):453-464. PubMed ID: 27013473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer.
    Chan YN; Jheng YW; Wang PJ; Chen CY; Lin MW; Wang YJ
    Clin J Oncol Nurs; 2019 Oct; 23(5):494-501. PubMed ID: 31538967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
    Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
    Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.
    Guijosa A; Freyria A; Espinosa-Fernandez JR; Estrada-Mena FJ; Armenta-Quiroga AS; Ortega-Treviño MF; Catalán R; Antonio-Aguirre B; Villarreal-Garza C; Perez-Ortiz AC
    Clin Transl Sci; 2022 Oct; 15(10):2403-2436. PubMed ID: 35892315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Taxanes: an overview of the pharmacokinetics and pharmacodynamics.
    Vaishampayan U; Parchment RE; Jasti BR; Hussain M
    Urology; 1999 Dec; 54(6A Suppl):22-9. PubMed ID: 10606281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients.
    Monfort SM; Pan X; Patrick R; Ramaswamy B; Wesolowski R; Naughton MJ; Loprinzi CL; Chaudhari AMW; Lustberg MB
    Breast Cancer Res Treat; 2017 Jul; 164(1):69-77. PubMed ID: 28374323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SNPs and taxane toxicity in breast cancer patients.
    Bosó V; Herrero MJ; Santaballa A; Palomar L; Megias JE; de la Cueva H; Rojas L; Marqués MR; Poveda JL; Montalar J; Aliño SF
    Pharmacogenomics; 2014; 15(15):1845-58. PubMed ID: 25495407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuromuscular ultrasound for taxane peripheral neuropathy in breast cancer.
    Lycan TW; Hsu FC; Ahn CS; Thomas A; Walker FO; Sangueza OP; Shiozawa Y; Park SH; Peters CM; Romero-Sandoval EA; Melin SA; Sorscher S; Ansley K; Lesser GJ; Cartwright MS; Strowd RE
    Muscle Nerve; 2020 May; 61(5):587-594. PubMed ID: 32052458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managing taxane toxicities.
    Markman M
    Support Care Cancer; 2003 Mar; 11(3):144-7. PubMed ID: 12618923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.
    Sucheston-Campbell LE; Clay-Gilmour AI; Barlow WE; Budd GT; Stram DO; Haiman CA; Sheng X; Yan L; Zirpoli G; Yao S; Jiang C; Owzar K; Hershman D; Albain KS; Hayes DF; Moore HC; Hobday TJ; Stewart JA; Rizvi A; Isaacs C; Salim M; Gralow JR; Hortobagyi GN; Livingston RB; Kroetz DL; Ambrosone CB
    Pharmacogenet Genomics; 2018 Feb; 28(2):49-55. PubMed ID: 29278617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy-induced peripheral neuropathy among patients with ovarian cancer.
    Jin L; Zhang Y; Yang W
    Int J Gynaecol Obstet; 2020 Jun; 149(3):303-308. PubMed ID: 32133643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients.
    Johnson C; Pankratz VS; Velazquez AI; Aakre JA; Loprinzi CL; Staff NP; Windebank AJ; Yang P
    J Neurol Sci; 2015 Feb; 349(1-2):124-8. PubMed ID: 25586538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
    Hirsh V; Okamoto I; Hon JK; Page RD; Orsini J; Sakai H; Zhang H; Renschler MF; Socinski MA
    J Thorac Oncol; 2014 Jan; 9(1):83-90. PubMed ID: 24346096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives.
    da Costa R; Passos GF; Quintão NLM; Fernandes ES; Maia JRLCB; Campos MM; Calixto JB
    Br J Pharmacol; 2020 Jul; 177(14):3127-3146. PubMed ID: 32352155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.